> Detailanzeige

Mey, Ulrich J. M.; Brugger, Wolfram; Schwarb, Heike; Pederiva, Stefanie; Schwarzer, Andreas; Dechow, Tobias; Jehner, Paul; Rauh, Jacqueline; Taverna, Christian J.; Schmid, Mathias; Schmidt‐Hieber, Martin; Doerfel, Steffen; Fischer, Natalie; Ruefer, Axel; Ziske, Carsten; Knauf, Wolfgang; Cathomas, Richard; von Moos, Roger; Hitz, Felicitas; Sauter, Rafael; Hiendlmeyer, Elke; Cantoni, Nathan; Bargetzi, Mario; Driessen, Christoph

Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd‐line therapy for relapsed and refractory multiple myeloma – a phase II trial

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd‐line therapy for relapsed and refractory multiple myeloma – a phase II trial
  • Beteiligte: Mey, Ulrich J. M.; Brugger, Wolfram; Schwarb, Heike; Pederiva, Stefanie; Schwarzer, Andreas; Dechow, Tobias; Jehner, Paul; Rauh, Jacqueline; Taverna, Christian J.; Schmid, Mathias; Schmidt‐Hieber, Martin; Doerfel, Steffen; Fischer, Natalie; Ruefer, Axel; Ziske, Carsten; Knauf, Wolfgang; Cathomas, Richard; von Moos, Roger; Hitz, Felicitas; Sauter, Rafael; Hiendlmeyer, Elke; Cantoni, Nathan; Bargetzi, Mario; Driessen, Christoph
  • Erschienen: Wiley, 2017
  • Erschienen in: British Journal of Haematology
  • Sprache: Englisch
  • DOI: 10.1111/bjh.14481
  • ISSN: 0007-1048; 1365-2141
  • Schlagwörter: Hematology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Summary</jats:title><jats:p>The combination of lenalidomide (Revlimid<jats:sup>®</jats:sup>, R) and dexamethasone (d) is a standard regimen for patients with relapsed/refractory multiple myeloma (rr<jats:styled-content style="fixed-case">MM</jats:styled-content>). With this regimen, only a small fraction of patients will achieve high quality responses [≥ very good partial response (<jats:styled-content style="fixed-case">VGPR</jats:styled-content>)]. The combination of bendamustine (B), lenalidomide and dexamethasone (<jats:styled-content style="fixed-case">BR</jats:styled-content>d) has shown high efficacy in patients with advanced rr<jats:styled-content style="fixed-case">MM</jats:styled-content>. However, dose‐limiting haematotoxicity restricted its use in extensively pre‐treated patient populations. This prospective, multicentre Phase <jats:styled-content style="fixed-case">II</jats:styled-content> study evaluated the efficacy and safety of <jats:styled-content style="fixed-case">BR</jats:styled-content>d in rr<jats:styled-content style="fixed-case">MM</jats:styled-content> patients with one prior line of therapy. Fifty patients were enrolled (median age 68·5 years [range 46–83]) and were treated with B 75 mg/m<jats:sup>2</jats:sup> days 1, 2; R 25 mg days 1–21 and d (40/20 mg) days 1, 8, 15 and 22, for 6 28‐day induction cycles, followed by 12 cycles with Rd alone. Pegfilgrastim was administered according to protocol‐defined criteria. The study aimed to demonstrate a complete response (<jats:styled-content style="fixed-case">CR</jats:styled-content>)/<jats:styled-content style="fixed-case">VGPR</jats:styled-content> rate of &gt;40% after induction therapy. Of 45 evaluable patients, 23 (51%) achieved a <jats:styled-content style="fixed-case">CR</jats:styled-content>/<jats:styled-content style="fixed-case">VGPR</jats:styled-content>. Grade 4 neutropenia or thrombocytopenia occurred in 17 (34%) and 8 (16%) of patients, respectively. <jats:styled-content style="fixed-case">BR</jats:styled-content>d is a safe and efficacious regimen as a second line treatment for rr<jats:styled-content style="fixed-case">MM</jats:styled-content>, leading to high quality responses in a considerable proportion of patients.</jats:p>